RenovoRx, Inc. (RNXT): who owns it and who trades it
As of Nov 16, 2026, RNXT insiders reported 10 purchases worth $84.5K in the last 12 months. The largest buyer was Ramtin Agah (Director), with $56K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling RenovoRx
From the latest filingsOverall: more buying than selling. Insiders mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, RNXT insiders reported $84.5K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 19, 2026 | Mark Voll | CFO | Purchase | 25,000 | $0.79 | $19.8K | Form 4 |
| Jan 21, 2026 | Ramtin Agah | Director | Purchase | 10,000 | $1.00 | $10K | Form 4 |
| Dec 31, 2025 | Ramtin Agah | Director | Purchase | 9,795 | $0.86 | $8.4K | Form 4 |
| Dec 30, 2025 | Ramtin Agah | Director | Purchase | 205 | $0.83 | $170 | Form 4 |
| Dec 18, 2025 | Shaun Bagai | CEO | Purchase | 5,000 | $0.90 | $4.5K | Form 4 |
| Dec 17, 2025 | Shaun Bagai | CEO | Purchase | 5,000 | $0.85 | $4.2K | Form 4 |
| Dec 16, 2025 | Ramtin Agah | Director | Purchase | 12,000 | $0.85 | $10.2K | Form 4 |
| Dec 5, 2025 | Ramtin Agah | Director | Purchase | 10,000 | $0.96 | $9.6K | Form 4 |
| Nov 24, 2025 | Ramtin Agah | Director | Purchase | 12,000 | $0.80 | $9.6K | Form 4 |
| Nov 21, 2025 | Ramtin Agah | Director | Purchase | 10,000 | $0.80 | $8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Ramtin Agah | Chief Medical Officer, Director | $56K | – | Jan 21, 2026 |
| Mark Voll | Chief Financial Officer | $19.8K | – | May 19, 2026 |
| Shaun Bagai | Chief Executive Officer, Director | $8.8K | – | Dec 18, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RNXT short interest
Low short interest. 2.1% of RNXT shares are sold short: about 1 share in 48. Over the last 12 reports the number of shares short went up 160%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 997,993 RNXT shares were sold short, 2.1% of the shares outstanding, up 15.4% from the report before. At the average daily volume of 284,652 shares, buying them all back would take about 3.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 997,993 | 2.07% | +15% | 284,652 | 3.5 |
| Oct 15, 2026 | 864,570 | 1.92% | -9% | 528,258 | 1.6 |
| Sep 30, 2026 | 946,982 | 2.10% | +41% | 597,351 | 1.6 |
| Sep 15, 2026 | 673,558 | 1.49% | +56% | 2.06M | 1.0 |
| Aug 31, 2026 | 432,726 | 0.96% | -36% | 903,872 | 1.0 |
| Aug 14, 2026 | 674,017 | 1.49% | +138% | 553,338 | 1.2 |
| Jul 31, 2026 | 283,437 | 0.63% | -14% | 197,105 | 1.4 |
| Jul 15, 2026 | 327,868 | 0.73% | -5% | 195,541 | 1.7 |
| Jun 30, 2026 | 345,817 | 0.77% | -1% | 246,461 | 1.4 |
| Jun 15, 2026 | 349,247 | 0.78% | -16% | 302,495 | 1.1 |
| May 29, 2026 | 416,166 | 0.92% | +8% | 340,257 | 1.2 |
| May 15, 2026 | 384,039 | 0.85% | -24% | 265,929 | 1.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
RenovoRx company events
RenovoRx filed 12 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 20, 2026AnnouncementRenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement As previously disclosed, on December 31, 2025, RenovoRx, Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq… Filing
- Aug 13, 2026ResultsAmended an earlier report. Released financial results. Filing
- Aug 4, 2026AnnouncementRenovoRx, Inc. issued a press release announcing the Company’s expected participation in a JonesTrading key opinion leader webinar relating to pancreatic cancer and the Company’s technology platform to be held on August 13, 2026. Filing
- Jul 2, 2026ListingAs previously reported, on December 31, 2025, RenovoRx, Inc., a Delaware corporation received a deficiency notice from The Nasdaq Stock Market informing the Company that its common stock had failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital… Filing
- Jun 30, 2026VoteReported shareholder vote results. Filing
- May 14, 2026ResultsReleased financial results. Filing
- Mar 30, 2026AnnouncementIn addition to announcing certain financial results, the Company’s press release provides certain updates of the Company’s clinical trial and commercialization strategy described in such press release. Filing
- Mar 27, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Filing
- Mar 23, 2026AgreementRenovoRx, Inc., a Delaware corporation, entered into a securities purchase agreement in connection with a private placement offering by the Company to 15 accredited investors or qualified institutional buyers, five of whom are directors, officers or employees of the Company and the remaining are… Filing
- Feb 6, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Filing
- Jan 2, 2026ListingRenovoRx, Inc., a Delaware corporation received a deficiency notice from The Nasdaq Stock Market informing the Company that its common stock, par value $0.0001 per share, failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
RenovoRx financials
Famous investors that hold RNXT
2 of the 50 well-known investors we track reported holding RNXT in their latest 13F filing. The largest position is Jim Simons's, worth $1.7M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.12M | $1.7M | 0.0% | +9722% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 103,953 | $162K | 0.0% | -22% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RNXT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 6, 2026 | BOSTON SCIENTIFIC CORP | 13G/A | 0.0% |
| Nov 6, 2026 | BOSTON SCIENTIFIC CORP | 13G/A | 0.0% |
Questions about RenovoRx, Inc. (RNXT) stock
Are RNXT insiders buying or selling?
In the last 12 months, RNXT insiders reported 10 open-market purchases worth $84.5K and no sales. The latest trade was on May 19, 2026. See every trade.
What is the short interest in RNXT?
As of Oct 30, 2026, 997,993 RNXT shares were sold short, 2.1% of the shares outstanding, up 15.4% from the report before. At the average daily volume of 284,652 shares, buying them all back would take about 3.5 trading days (days to cover). See the history.
Which famous investors hold RNXT?
2 of the 50 well-known investors we track reported RNXT in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $1.7M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.